Mark Kaplan
About Mark Kaplan
Mark Kaplan is the Senior Director, Lymphoma Disease Head, Translational Medicine at Bristol Myers Squibb in the New York City Metropolitan Area, with over 20 years of experience in drug discovery and development.
Current Title and Role
Mark Kaplan is currently the Senior Director, Lymphoma Disease Head, Translational Medicine at Bristol Myers Squibb. Based in the New York City Metropolitan Area, he focuses on leading efforts in translational medicine specifically targeting lymphoma, driving research and development in this critical therapeutic area.
Professional Experience at Bristol Myers Squibb
Kaplan has a significant tenure at Bristol Myers Squibb, having previously served as Director, Translational Medicine from 2020 to 2023 in Summit, NJ. In his current capacity, he continues to spearhead innovative research and foster advancements in medicine that aim to improve patient outcomes and healthcare standards.
Previous Roles in Translational Research
Prior to his current role, Kaplan amassed extensive experience across several prestigious organizations. He served as Director, Translational Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson in New Brunswick, NJ for six months in 2020, and as Director, Translational Research at QUENTIS THERAPEUTICS INC from 2018 to 2019 in New York. At Pfizer, he held multiple positions from 2011 to 2018, including Translational Oncology Lead and Biomarker Strategy Lead.
Early Career and Diverse Experience
Kaplan's early career includes roles at Roche as Principal Research Scientist and Head of Functional Biology, and at Celera Genomics as Staff Scientist. He also contributed to research at Exelixis and Deltagen, and began his postdoctoral fellowship at the University of Wisconsin-Madison. His comprehensive experience spans various aspects of translational research and development across leading pharmaceutical companies.
Education Background
Kaplan holds a Doctor of Philosophy (PhD) in Biophysics from the University of California, San Francisco, achieved from 1993 to 1998. He also earned a Bachelor of Arts (BA) in Biochemistry from Harvard University, completed from 1989 to 1993. His educational foundation has been instrumental in shaping his career in translational medicine and drug discovery.